Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Blood (2022) 140 (Supplement 1): 1183–1184.

https://doi.org/10.1182/blood-2022-156121

Published: 2022

Journal Articles

A Phase II Clinical Trial of "Off-the-Shelf" NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies

Jeremy L. Ramdial, Lorlyn Clemente-Sevilla, Doris Soebbing, Bouthaina S. Dabaja, Peter F Thall, Gheath Alatrash, Amin M Alousi, Rohtesh S. Mehta, Uday R Popat, Partow Kebriaei, Betul Oran, Katy Rezvani, Elizabeth J Shpall, Richard E Champlin

Blood (2022) 140 (Supplement 1): 7484–7485.

https://doi.org/10.1182/blood-2022-170663

Published: 2022

Journal Articles

First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Blood (2022) 140 (Supplement 1): 2120–2122.

https://doi.org/10.1182/blood-2022-159183

Published: 2022

Journal Articles

Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)

Betul Oran, Richard E Champlin, Peter F Thall, Jessica M McCarty, Wen Zhang, David Marin, Rohtesh S. Mehta, Amin M Alousi, Gheath Alatrash, Uday R Popat, Hagop Kantarjian, Qaiser Bashir, Elizabeth J Shpall, Marina Konopleva

Blood (2022) 140 (Supplement 1): 10561–10562.

https://doi.org/10.1182/blood-2022-159312

Published: 2022

Journal Articles

A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Blood (2021) 138 (Supplement 1): 3941.

https://doi.org/10.1182/blood-2021-149807

Published: 2021

Journal Articles

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

Blood (2021) 138 (Supplement 1): 556.

https://doi.org/10.1182/blood-2021-152450

Published: 2021

Journal Articles

Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting

Betul Oran, MDMS, Amin M. Alousi, MD, Rohtesh S. Mehta, MDMPH,MS, David Marin, Partow Kebriaei, MD, Uday R. Popat, MD, Amanda L. Olson, Jessica M McCarty, RN, Jennifer D Ramos, RN, Roland Bassett, Harold N. Keer, MDPhD, Peter F Thall, PhD, Richard E. Champlin, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-134204

Published: 2020

Journal Articles

Trial in Progress: A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Qaiser Bashir, MD, Peter F Thall, PhD, Dawen Sui, Cristina Knape, Jitesh Kawedia, BPharm, Muzaffar H. Qazilbash, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-139853

Published: 2020

Journal Articles

Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation

Betul Oran, MDMS, Gheath Alatrash, Amin M. Alousi, MD, Rohtesh S. Mehta, MDMPH,MS, Chitra Hosing, MD, Uday R. Popat, MD, Jin S. Im, Jessica M McCarty, RN, Jennifer D Ramos, RN, Harold N. Keer, MDPhD, Peter F Thall, PhD, Richard E. Champlin, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-134272

Published: 2020

Journal Articles

Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

Blood (2019) 134 (Supplement_1): 3596.

https://doi.org/10.1182/blood-2019-126028

Published: 2019

Journal Articles

A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

Blood (2019) 134 (Supplement_1): 257.

https://doi.org/10.1182/blood-2019-124921

Published: 2019

Journal Articles

Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Betul Oran, MDMS, Marcos de Lima, MD, Guillermo Garcia-Manero, MD, Peter F Thall, Ruitao Lin, Amin M. Alousi, MD, Chitra Hosing, MD, Partow Kebriaei, MD, Uday Popat, MD, Sergio Giralt, MD, Sairah Ahmed, MD, Elizabeth J. Shpall, MD, Borje S Andersson, MD PhD, Qaiser Bashir, MD MBBS, Stefan O. Ciurea, Katy Rezvani, MD PhD, Glenda Woodworth, BSN, OCN, RN, Richard E Champlin, MD

Blood (2018) 132 (Supplement 1): 971.

https://doi.org/10.1182/blood-2018-99-111582

Published: 2018

Journal Articles

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Yago Nieto, MD PhD, Peter F Thall, Benigno C Valdez, PhD, Junsheng Ma, MS, Melissa Timmons, Michelle Trapp, Sairah Ahmed, MD, Elizabeth J Shpall, MD, Roy B Jones, MDPhD, Chitra Hosing, MD, Paolo Anderlini, Uday Popat, MD, Muzaffar H. Qazilbash, MD, Amin Alousi, MD, Alison M Gulbis, PharmD, Celina Ledesma, Richard E. Champlin, MD, Borje S Andersson, MDPhD

Blood (2017) 130 (Supplement 1): 1966.

https://doi.org/10.1182/blood.V130.Suppl_1.1966.1966

Published: 2017

Journal Articles

A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma

Blood (2017) 130 (Supplement 1): 399.

https://doi.org/10.1182/blood.V130.Suppl_1.399.399

Published: 2017

Journal Articles

Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation

Blood (2016) 128 (22): 4547.

https://doi.org/10.1182/blood.V128.22.4547.4547

Published: 2016

Journal Articles

Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial

Blood (2016) 128 (22): 504.

https://doi.org/10.1182/blood.V128.22.504.504

Published: 2016

Journal Articles

Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results

Nina Shah, MD, Peter F Thall, PhD, Denái R. Milton, Qaiser Bashir, MD, Simrit Parmar, MD, Pei Lin, MD, Partow Kebriaei, MD, Yago Nieto, MD PhD, Uday R. Popat, MD, Chitra Hosing, MD, Amanda Cornelison, Ruby Delgado, Elizabeth J. Shpall, MD, Robert Z. Orlowski, MD PhD, Richard E. Champlin, MD, Muzaffar Qazilbash, MD

Blood (2016) 128 (22): 2269.

https://doi.org/10.1182/blood.V128.22.2269.2269

Published: 2016

Journal Articles

Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia

Blood (2016) 128 (22): 64.

https://doi.org/10.1182/blood.V128.22.64.64

Published: 2016

Journal Articles

Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma

Yago Nieto, MD, PhD, Benigno C. Valdez, PhD, Peter F Thall, PhD, Wei Wei, MS, Roy Jones, MD PhD, Chitra M. Hosing, MD, Sairah Ahmed, MD, Uday R. Popat, MD, Elizabeth J. Shpall, MD, Muzaffar Qazilbash, MD, Alison M Gulbis, Paolo Anderlini, MD, Nina Shah, MD, Qaiser Bashir, MD, Amin M. Alousi, MD, Yasuhiro Oki, MD, Fredrick B. Hagemeister, MD, Richard E. Champlin, MD, Borje S. Andersson, MD PhD

Blood (2015) 126 (23): 1992.

https://doi.org/10.1182/blood.V126.23.1992.1992

Published: 2015

Journal Articles

Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma

Nina Shah, Peter F. Thall, PhD, Patricia S Fox, MS, Qaiser Bashir, Jatin J. Shah, Simrit Parmar, Partow Kebriaei, MD, Yago Nieto, Uday R. Popat, MD, Chitra M Hosing, MD, Krina K. Patel, MD, Pei Lin, MD, Elizabeth J Shpall, MD, Robert Z. Orlowski, PhD MD, Richard E. Champlin, Muzaffar H. Qazilbash, MD

Blood (2014) 124 (21): 3981.

https://doi.org/10.1182/blood.V124.21.3981.3981

Published: 2014

NARROW

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

A Phase II Clinical Trial of "Off-the-Shelf" NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies

First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)

A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting

Trial in Progress: A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation

Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma

Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation

Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial

Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results

Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia

Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma

Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only